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Follistatin N terminus differentially regulates muscle
size and fat in vivo
Hui Zheng1,2,3, Chunping Qiao1,3, Ruhang Tang1, Jianbin Li1, Karen Bulaklak1, Zhenhua Huang1,
Chunxia Zhao1, Yi Dai1, Juan Li1 and Xiao Xiao1
Delivery of follistatin (FST) represents a promising strategy for both muscular dystrophies and diabetes, as FST is a robust
antagonist of myostatin and activin, which are critical regulators of skeletal muscle and adipose tissues. FST is a multi-domain
protein, and deciphering the function of different domains will facilitate novel designs for FST-based therapy. Our study aims to
investigate the role of the N-terminal domain (ND) of FST in regulating muscle and fat mass in vivo. Different FST constructs
were created and packaged into the adeno-associated viral vector (AAV). Overexpression of wild-type FST in normal mice greatly
increased muscle mass while decreasing fat accumulation, whereas overexpression of an N terminus mutant or N terminus-
deleted FST had no effect on muscle mass but moderately decreased fat mass. In contrast, FST-I-I containing the complete N
terminus and double domain I without domain II and III had no effect on fat but increased skeletal muscle mass. The effects of
different constructs on differentiated C2C12 myotubes were consistent with the in vivo finding. We hypothesized that ND was
critical for myostatin blockade, mediating the increase in muscle mass, and was less pivotal for activin binding, which accounts
for the decrease in the fat tissue. An in vitro TGF-beta1-responsive reporter assay revealed that FST-I-I and N terminus-mutated
or -deleted FST showed differential responses to blockade of activin and myostatin. Our study provided direct in vivo evidence
for a role of the ND of FST, shedding light on future potential molecular designs for FST-based gene therapy.
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INTRODUCTION
Myostatin, also known as growth/differentiation factor-8
(GDF8), is a member of the transforming growth factor β
(TGF-β) superfamily. Myostatin acts as a negative regulator of
muscle development.1–5 The biological function of myostatin
has raised the possibility of using its inhibitors to promote
muscle growth and improve disease phenotypes in a variety of
primary and secondary myopathies, including muscular
dystrophies.6–11 Myostatin inhibitors include the myostatin
propeptide,1 follistatin (FST)12 and the FST-related gene
(FLRG),13 as well as growth and differentiation factor-
associated serum protein-1 (GASP-1).14 Among them, FST is
the most potent inhibitor.
Activin is another member of the TGF-β superfamily and
binds to FST with high affinity.15,16 It is involved in a variety of
physiological functions, including metabolism, immunity and
reproduction.17–20 Activin B is involved in energy expenditure,
whereas Activin A has a critical role in proliferation and
differentiation of human adipose progenitor cells.20,21 The
significant increase in activin A, which may lead to insulin
resistance and inflammation, is more often observed in obese
subjects than lean ones.21,22 In addition, our recent study
indicates that overexpression of FST in the pancreas of the type
2 diabetic mouse ameliorates disease symptoms by promoting
β-cell proliferation via bioneutralization of activin A and
myostatin.23 Therefore, blocking activin A and myostatin
through delivery of FST in diabetic patients could represent a
new therapeutic avenue.
FST, first recognized as a follicle-stimulating hormone (FSH)
inhibitor, is an autocrine glycoprotein that is expressed in
nearly all tissues of higher animals.24,25 Its primary function is
binding and bioneutralization of members of the TGF-β
superfamily, particularly activins, followed by myostatin
(growth/differentiation factor-8, GDF8), GDF9, and BMPs 2,
5, 7 and 8.26,27
FST is synthesized in three protein isoforms: FST-288,
FST-303 and FST-315.16,28,29 FST-315 is the predominant form
accounting for 95% of all FSTs.25 It consists of the N-terminal
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domain (ND), three follistatin domains (FSD1, FSD2 and
FSD3) and a C-terminal tail containing several acidic residues,
which decrease its heparin binding affinity.25,30 FST-315 is
found primarily in blood circulation. FST-288 lacks the
C-terminal tail and is a tissue bound isoform, whereas
FST-303 contains only part of the C-terminal tail and is
gonad-specific.31
It is widely accepted that FSD1 and FSD2 significantly
contribute to binding affinity, but findings concerning the
importance of the ND and whether it is necessary for activin
and myostatin binding are mixed.32–36 Structural and bio-
chemical evidence have suggested that deletion or truncation of
the ND or disruption of N-terminal disulfides each reduced
activin binding to o5% of the expressed wild-type (WT) FST
or abolished it.27,37,38 However, previous studies of the FST
crystal structure have indicated that the ND had important
roles in myostatin binding but not in activin binding.36 An FST
construct consisting of the complete ND followed by two
FSD1s was reported to exhibit high affinity for myostatin
binding, but not activin binding.39 This indicates that different
domains of FST differentially regulate FST-myostatin and FST-
activin interactions. Given the controversial function of ND of
FST in binding with myostatin and activin, this study aims to
investigate the ND of FST via an in vivo mouse study.
MATERIALS AND METHODS
Construction of FST plasmids and AAV vector production
The mouse FST cDNA (GenBank accession number: NM_008046)
was generated by reverse transcription polymerase chain reaction
(PCR) method from the ovary tissues of normal female ICR mice, and
the primers used were 5′-CAG GAT GGT CTG CGC CAG-3′ and
5′-GTT TTG CCC AAA GGC TAT GTC-3′. The PCR product was
initially cloned into the EcoRV site of pBluescript-KS(+) (BSKS)
backbone. Then, the SacI–XhoI fragment of pBSKS-FST was cloned
into an AAV vector plasmid via sticky end ligation. The mouse-FS-N
(mutated) sequence (30–92 amino acids of the N terminus of wild-
type FST were replaced with the 29–150 amino acids of GenBank
XM_005619457) was directly synthesized by the GenScript company
(Piscataway, NJ 08854). The FS-N(− ) (30–92 amino acids of the N
terminus were deleted) and FST-I-I (containing the complete N
terminus and double domain I without domain II and III) were
generated by site-directed mutagenesis based upon the pBSKS-FST
template. The various FST genes were cloned into the same AAV
vector plasmid (pXX-CAG) under the transcriptional control of the
chicken β-actin (CAG) promoter including cytomegalovirus (CMV)
enhancers and a large synthetic intron (Figure 1).40
Recombinant viral vector stocks were produced according to the
plasmid co-transfection method.41 Viral particles were purified twice
by CsCl density gradient ultracentrifugation using a previously
published protocol.42 Vector titers were determined by the DNA
dot-blot method and were in the range of 2 ×1012 to 5× 1012 vector
genomes (vg) per ml.
Mice and vector administration
All experiments involving animals were approved by the University of
North Carolina Animal Care and Use Committee and the male ICR
mice were purchased from Taconic. All the vectors were delivered into
4-week-old ICR mice (18–22 g) by tail vein injection. AAV9-CAG-
mouse-FST was delivered at a final dose of 2.5 × 1011 vg per mouse, and
other viruses were injected at 5× 1011 vg per mouse. Control mice were
injected with PBS. Body weight of the mice was measured once a week
starting from 2 weeks after injection until the mice were 12 weeks old.
Muscle and fat morphology, morphometric analysis and
immunofluorescence staining
TA (tibialis anterior), GAS (gastrocnemius) and other muscles were
collected at the indicated age, and H&E (hematoxylin and eosin)
staining was performed on 9-μm frozen sections using a previously
reported method.7 The abdominal white fat tissue was separated from
other tissues after opening the abdominal wall of the mice. Total
Figure 1 FST vector constructs. (a) Mouse FST cDNA. (b) FST-N-mutated plasmid containing a mutated N terminus. (c) FST-N(− )
plasmid containing deleted N terminus. (d) FST-I-I plasmid containing two copies of domain I with a complete N terminus SP, signal
peptide; ITR, inverted terminal repeats; CAG, a hybrid promoter contains the cytomegalovirus enhancer, chicken beta-actin promoter and
rabbit beta-globin intron. N, N-terminal; FSD I, FST domain I; FSD II, FST domain II; FSD III, FST domain III; C, C terminus.
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abdominal white fat from each mouse was weighed and H&E staining
was performed on 5-μm paraffin embedded sections.
For morphometric analysis, thin cryosections of TA and GAS
muscles from treated and control mice (four mice per group) were
subjected to a rabbit polyclonal antibody recognizing human dystro-
phin rod 22 and rod 23 region (diluted 1:500, generated in Dr Xiao’s
lab) staining for displaying the periphery of the muscle fibers.43
Pictures were taken, and the total area of each myofiber was analyzed
with MetaMorph software (Molecular Devices, Sunnyvale, CA, USA).
The average myofiber size (from at least 150 myofibers per mouse)
was calculated and used for the statistical analysis.
For immunofluorescent staining, frozen sections were permeabi-
lized with permeabilization buffer (1% Triton X-100 in PBS) for
15 min at room temperature. After blocking with 10% horse serum
(HS) in PBS, the sections were incubated with rabbit anti-phosphory-
lated-Smad2/3 antibody (1:500, Santa Cruz Biotechnology INC, Cat#
sc-11769R) overnight. The ratios of phosphorylated-Smad2/3 positive
muscle fibers to total muscle fibers were calculated from 40× images.
All TA and GAS muscles were imaged and total muscle fiber numbers
were counted by counting DAPI (4′,6-diamidine-2′-phenylindole
dihydrochloride)-stained nuclei. For each mouse, approximately 500
muscle fibers of TA and 1000 of GAS were counted.
Western blotting
Protein of the TA muscle (or differentiated C2C12 cells) was extracted
using lysis buffer containing 1% Triton X-100, 20 mM Tris-HCL
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 5 mM NaF, 2.5 mM sodium
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 μg ml−1
leupeptin, 0.1 mM PMSF and a cocktail of protease inhibitors (Sigma,
St Louis, MO, USA, Cat# P0044). 25 μg of protein per lane and
prestained molecular weight markers (Bio-Rad, Hercules, CA, USA Cat#
161–0318) were separated with 12% SDS/PAGE gels and then
transferred to polyvinylidene fluoride (PVDF) membranes. After block-
ing at room temperature for 1 h with a solution containing 3% bovine
serum albumin (BSA, Fisher Scientific, Waltham, MA, USA, Cat#
137043) in 10 mM Tris-HCl (pH 7.5), 100 mM NaCl and 0.1% Tween-
20 (TBST), membranes were incubated overnight at 4 °C with 1:500
rabbit polyclonal anti-phosphorylated-AKT (Ser473) (Cell Signaling,
Danvers, MA, USA, Cat# 9271), rabbit anti-phosphorylated-Smad2/3
antibody (1:1000), or GAPDH (1:5000, Sigma, Cat# G9545), followed
by 1:5000 horseradish peroxidase (HRP)-conjugated secondary antibody
incubation. A chemiluminescent detection kit (PerkinElmer, Waltham,
MA, USA, Cat# 203–100901) was used to develop the membranes.
Culture and treatment of C2C12 cell line
The conditioned media was produced by transfection of individual
plasmid into the 293 cells using the calcium phosphate method. Seven
to 12 h after transfection, the media was replaced by Opti-Mem media
(Gibco, Life Technologies, Carlsbad, CA USA. REF # 31985-070). The
supernatant of the transfected 293 cells was collected 48–60 h after
transfection as the conditioned media.
C2C12 cells were cultured in growth medium consisting of
Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Life Technol-
ogies, Cat# 1676966), supplemented with 10% Fetal Bovine Serum
(FBS, HyClone, GE Healthcare Life Sciences, Logan, UT, USA) and
1/3 conditioned media. Differentiation was initiated 24 h after seeding
by changing to conditioned differentiation medium, consisting of
DMEM, supplemented with 2% HS and 1/3 conditioned media. The
conditioned differentiation medium was renewed every 2–3 days until
C2C12 cells were fully differentiated.
To analyze changes in myotube size, differentiated myotubes were
fixed with ice-cold acetone and methanol (1:1) for 10 min at 4°. After
washing with PBS three times, cells were permeabilized with 1%
Triton X-100 in PBS for 10 min, blocked with 10% horse serum for
1 h, then subjected to dystrophin R22R23 antibody staining for
displaying peripheral edges.
The diameter of the myotubes was measured using Adobe Photo-
shop software (Adobe, Los Altos, CA, USA). The width of each
myotube was measured three times in different spots and the average
reading was obtained. For each group, a minimum of 50 myofibers
were measured.
Luciferase reporter assays
The 293-cell line was utilized in an activin blockade assay; 293 cells
were plated onto 6-well plates at ~ 2× 105 cells per well 1 day before
transfection. For all wells, the TGF-beta1-responsive luciferase reporter
p3TP-Lux (0.1 μg per well) and transfection control CMV-LacZ
plasmids (0.1 μg per well) were transfected using the calcium
phosphate method. In addition, distinct plasmids (2.8 μg per well)
such as pBluescript-KS(+), pAAV-CAG-mouse-FST, pAAV-CAG-
mouse-N(− ), pAAV-CAG-mouse-N(mutated) or pAAV-CAG-
mouse-FST-I-I were transfected into each well, respectively. Six to
eight hours after transfection, the transfection media were replaced
either by activin-conditioned media (DMEM supplemented with 2%
FBS and 1/3 activin-conditioned media) or Bluescript-KS(+)-condi-
tioned media. The transfected cells were collected 36 h after transfec-
tion. Luciferase activities were measured with a luciferase assay kit
(Promega, Cat# E1501), and LacZ activity was measured using the
classic colorimetric ONPG assay method.44 The luciferase activities
were normalized by LacZ activity.
For the myostatin blockade experiment, the R-1B L17 cells were
used.45 The R-1B L17 cells were plated onto 6-well plates at ~2.5×105
cells per well 1 day before transfection. Transfection was performed with
Lipofectamine 3000 transfection kit (Invitrogen, Life Technologies,
Carlsbad, CA, USA, Cat# 1662152). For all the wells, the 3TP-Lux
plasmid (0.2 μg per well), transfection control CMV-LacZ plasmids
(0.1 μg per well) and pCMV5b-ALK4 plasmids (1.1 μg per well) were
transfected. In addition, different induction and control plasmids (1.1 μg
per well) were added. Six to eight hours after transfection, the
transfection media were replaced either by myostatin-conditioned media
or Bluescript-KS(+)-conditioned media. The transfected cells were
harvested and luciferase activities were examined as described above.
Statistical analysis
Values are expressed as the mean± s.e.m. All statistical analyses were
performed in GraphPad Prism software using a one- or two-way
analysis of variance (ANOVA) with a Dunnett post-test. Po0.05 was
considered statistically significant.
RESULTS
Delivery of N(− ) or N-mutant FST in adult mice failed to
increase skeletal muscle mass
We constructed AAV vectors containing intact, N terminus-
mutated and -deleted FST genes. In addition, we created an
FST-I-I construct comprised of the full N terminus, double
domain I and C terminus without domains II and III. It has
been reported that the FST domain I (FSD1) is responsible for
the myostatin inhibition effect, and the FST-I-I construct
(Figure 1d) retains myostatin binding with weaker activin
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blockade activity.33,35 The FST genes were driven by ubiquitous
CAG promoter (see the ‘Materials and Methods’ section for
details), and the plasmids were named pAAV-CAG-mouse-FST
(Figure 1a), pAAV-CAG-mouse-FST-NM (mutated)
(Figure 1b), pAAV-CAG-mouse-FST-N(− ) (Figure 1c) and
pAAV-CAG-FST-I-I (Figure 1d), respectively. The expression
of FST-based plasmids was revealed via western blot
(Supplementary Figure 1).
Figure 2 Delivery of N(− ) or NM to adult mice failed to increase skeletal muscle mass. (a) Body weight of the AAV9-CAG-mouse-FST
group (large square) was significantly increased compared with the control group from 6 weeks old (2 weeks after injection), while that of
the AAV9-CAG-mouse-FST-I-I group (diamond) was slightly increased. There was no difference in mouse weight in the AAV9-CAG-mouse-N
(− ) (small square) group and AAV9-CAG-mouse-FST-NM (asterisk) group compared with the control group (triangle). (b) Images of hind leg
muscles of different groups. Compared with the control group, muscles of the FST-I-I group were slightly larger and muscles of the FST
group were the largest. There was no difference among N(− ), NM and control groups. (c–g) Muscle weights of different groups. TA muscle
weight (c), GAS muscle weight (d), the triceps muscle weight (e), the quadriceps muscle weight (f) and the diaphragm muscle weight (g)
increased in FST and FST-I-I young adult mice group, whereas those of N(− ) and NM did not. N=4 for all groups unless otherwise
specified. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001 compared with control ICR mice.
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The four different AAV constructs were packaged into the
AAV9 vector, which has been shown to have a superior ability
to transduce cardiac muscle, skeletal muscle and liver cells via
systemic delivery.46,47 The AAV9 vectors containing varied FST
genes were injected into 4-week-old adult mice by the tail vein
(2.5–5×1011 vg per mice). The control group was injected with
saline PBS. After vector administration, the mice were periodi-
cally weighed to determine whether their weight was affected
by the treatment. As shown in Figure 2a, compared with the
body weight of saline-treated control mice (30.2 g), we
observed a significant weight increase in the AAV9-CAG-
mouse-FST group (FST, 35.6 g, P= 0.006), an intermediate
weight increase in the AAV9-CAG-mouse-Follistatin-I-I group
(FST-I-I, 33.7 g, P= 0.035), and no weight increase for AAV9-
CAG-mouse-Follistatin-N(− ) (N(− ), 30.9 g, P= 0.33) and
AAV9-CAG-mouse-Follistatin-N(mutated) (NM, 29.6 g,
P= 0.38) groups, starting from 2 weeks after vector injection
(6-week-old). The mice were euthanized 8 weeks after vector
delivery (12-week-old). Different muscle groups were carefully
dissected and weighed (Figure 2b). There was an obvious
increase in weight of major skeletal muscles after FST and FST-
I-I vector delivery, but no difference was found among control,
NM and N(− ) groups (Figure 2c–g).
Cryosections were made from various muscle groups and
H&E staining was performed to examine muscle fiber size
(Figure 3a). The expression of different FST constructs was
confirmed by immunofluorescent staining (Supplementary
Figure 2a) and western blot (Supplementary Figure 2b). Similar
to the results obtained from whole body and muscle weights,
obvious hypertrophy was found in the FST group (tibialis
anterior (TA) muscle: 2.17-fold over control, Po0.001; gastro-
cnemius (GAS) muscle: 2.8-fold over control, Po0.001).
A minor increase was observed in the FST-I-I muscles (TA:
1.1-fold over control, P40.05; GAS: 1.4-fold over control,
Po0.05) (Figure 3b). The muscles from N(− ) and N
(mutated) groups displayed normal histology without changes
in myofiber size compared with those of untreated control
mice (Figure 3a and b). Because an increase in skeletal muscle
mass is a hallmark of myostatin inhibition, we conclude from
these data that the FST with an N terminus mutation or
deletion has lost its apparent myostatin blockade effect in vivo.
Involvement of signaling pathways in skeletal muscles by
FST-based constructs
To understand the molecular mechanisms of the FST con-
structs in skeletal muscles, IF staining and western blot were
performed to detect the relevant signaling pathways, particu-
larly the inhibition of Smad2/3 and the activation of insulin-
phosphoinositide 3-kinase (PI3K)-AKT pathways. The level of
intra-nuclear phosphorylated Smad2/3 (P-Smad) of the TA
muscle was examined by IF staining (Figure 3c). The percen-
tage of P-Smad2/3+ nuclei/total nuclei in the FST group was
significantly inhibited compared with the control mice
(17.7±6.4% vs 96.2± 3.5%, n= 3, Po0.0001), followed by
the FST-I-I group (43.8± 3.9% vs 96.2± 3.5%, Po0.0001)
(Figure 3d). Surprisingly, we also noticed inhibition of
P-Smad2/3 levels in both FST-N (mutated) (53.2± 2.6%,
Po0.001) and N(− ) (59.1±6.2%, Po0.001) groups compared
with the controls, albeit to a lesser extent (Figure 3d).
The PI3K–AKT pathway can also impact muscle fiber
size.48,49 To explore the role of this pathway in skeletal muscles
after injection of different FST-based constructs, western blot
was performed against phosphorylated AKT (P-AKT)
(Figure 3e). Both FST (2.1± 0.2-fold greater than the control
for the ratio of P-AKT/total AKT, n= 3, Po0.01) and FST-I-I
groups (2.1± 0.2-fold greater than the control, n= 3, Po0.05)
showed significant activation of P-AKT. There was only a
marginal increase in P-AKT expression in both N(− )
(1.2±0.02-fold greater than the control, n= 3, P40.05) and
NM (1.6± 0.1-fold greater than the control, n= 3, P40.05)
groups (Figure 3f). Our results indicated weak ligand binding
abilities and inefficient intracellular signaling mediated by both
N(− ) and NM constructs in skeletal muscles.
FST-N(− ) or FST-NM in adult mice partially decreased
white adipose tissue mass
The weight of white adipose tissue (WAT) from different
anatomical sites was evaluated during the tissue harvest
(Figure 4a). As expected, a significant decrease in WAT weight
was observed in the FST group (24.3±11.8% of the control,
Po0.001). In addition, we noticed a decrease in WAT weight
for both N(− ) (48.8±14.4% of the control, Po0.01) and NM
(57.1± 26.5% of the control, Po0.05) groups (Figure 4b).
However, there was no significant difference in WAT weight in
the FST-I-I group (98.0± 31.8% of the control, P40.05)
compared with the control (Figure 4b).
To examine individual adipocyte sizes, cryosections were
made and H&E staining was performed. Consistent with the
WAT weight data, we observed a significant decrease in
adipocyte sizes in the FST group. N(− ) and NM groups also
displayed smaller adipocyte sizes, whereas the FST-I-I group
did not change in size compared with the control (Figure 4c).
From these data, we concluded that FST with an N terminus
mutation or deletion were able to decrease white fat in vivo.
N terminus-mutated or -deleted FSTs minimally enhanced
differentiation of C2C12 myoblasts
To evaluate the in vitro effects of different FST constructs on
differentiation of myofibers, we investigated them on C2C12
myoblasts. The C2C12 cells were cultured in differentiation
media supplemented with conditioned media collected from
293 cells transfected with different constructs (GFP control,
mouse-FST, mouse-FST-N (mutated), mouse-N(− ) and
mouse-FST-I-I). After 4 days of differentiation, the FST group
appeared much larger than the control GFP group, followed by
the FST-I-I, NM and N(− ) groups (Figure 5a). Quantitation
data showed that the myofiber diameter of the FST group
(666.5±271.2 μm, n= 156, Po0.001) were 2.05-fold larger
than the control myotubes (323.5± 106.5 μm, n= 729), and
the FST-I-I group (596.0± 217.2 μm, n= 199, Po0.01) were
1.8-fold larger (Figure 5b). The NM group (482.2± 160.5 μm,
n= 217, Po0.05) and N(− ) group (414.9±161.7 μm, n= 187,
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P40.05) showed minimal enhancement by 1.5-fold and 1.3-
fold, respectively (Figure 5b).
It has been reported that myostatin binds to its receptor
complex ActRIIB/ALK4 or ALK5 on the skeletal muscle,
resulting in both activation of Smad2/3 and inhibition of the
PI3K intracellular signaling pathways. The alteration of these
two pathways impacts protein synthesis, which ultimately
causes muscle atrophy.48,49 To understand the molecular
Figure 3 Delivery of N(− ) or NM to adult mice failed to increase myofiber sizes in adult mice and had minimal involvement in relevant
signaling pathways. (a) H&E staining of TA and GAS muscles (20× ). Scale bar: 100 μm. (b) Quantification of muscle fiber size. TA and
GAS fiber size of FST were 2.2- and 2.8-fold over the control, respectively. Those of the FST-I-I muscles were 1.1- and 1.4-fold greater
than the control. However, N(− ) and NM muscles displayed normal histology without changes in myofiber size or number compared with
those of untreated control mice. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001 compared with control ICR mice.
(c) Immunofluorescent staining of muscle fibers against P-Smad2/3. Red indicates P-Smad2/3-positive cells, and blue indicates the
nucleus (DAPI-stained). (d) Quantification of the percentage of phospho-SMAD2/3 nuclear positive cells to total muscle fibers. In the FST
group, the percentage was significantly decreased compared with the control group (17.7 ±6.4% vs 96.2±3.5%), whereas the percentage
of FST-I-I was 43.8±3.9%, N(− ) was 59.1±6.2% and NM was 53.2±2.6%. (e) The expression of phosphorylated AKT (P-AKT, ser 473)
and total AKT (Tot AKT) was shown by western blot. (f) Semi-quantification of P-AKT expression shown in the western blot. Compared with
the control group, the expression of P-AKT to total AKT in FST was 2.1-fold greater, FST-I-I was 2.1-fold greater, N(− ) was 1.2-fold
greater and NM was 1.6-fold greater. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001 compared with control ICR mice. N=4 for
all groups.
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mechanisms in myotube diameter change caused by different
FST-based constructs, we performed a western blot against
P-Smad2/3 vs total Smad and P-AKT vs total AKT in C2C12
cells with different culture conditions. Western blots showed
that Smad2/3 was significantly inhibited in the FST group
(74.4% of the control for the ratio of P-Smad2/3/total Smad,
Po0.01), followed by the FST-I-I group (84.2% of the control,
Po0.05) (Figure 6a and b). NM and N(− ) had no apparent
influence on the expression of P-Smad2/3. In contrast, all the
constructs significantly upregulated AKT signaling in the
differentiated C2C12 cells, with the FST being the highest
(369.6% of the ratio of P-AKT/total AKT of control,
Po0.0001), followed by FST-I-I (310.4% of the control for
the ratio of P-AKT/total AKT, Po0.0001), N(− ) (282.8% of
control, Po0.001) and FST-N (mutated) (162.8% of the
control, Po0.001) (Figure 6c and d). These results indicate
that both blockade of Smad and activation of the AKT
pathways could contribute to enlargement of the differentiated
myotubes, and the N(− ) and NM constructs had minimal
effects on Smad signaling in cultured myotubes in vitro.
The effect of FST-based constructs on SMAD luciferase
reporter assay
Our data indicated that N(− ) and NM significantly decreased
white fat weight with a minimal impact on muscle mass.
Because it is well known that FST can markedly increase
muscle mass in normal mice through blockade of myostatin,1–5
we reasoned that decreased fat mediated by FST was mainly
through activin. We hypothesized that ND was critical for
myostatin blockade, but less pivotal for activin interaction. To
test this hypothesis, we utilized a luciferase reporter gene with
the 3TP promoter that contains three consecutive TPA (tetra-
decanoylphorbol-13-acetate) responsive elements and one
TGF-β responsive element (p3TP-Lux, Addgene, Cambridge,
MA, USA, Cat# 11767).50 This reporter system is often used to
test the transcriptional activity of TGF-β signaling.51–55
In the myostatin blockade reporter assay, four plasmids were
co-transfected into R-1B (L17) cells, a mink lung epithelial cell
line expressing very low amounts of TGF-β superfamily type I
receptor. These four plasmids include 3TP-Lux, a transfection
control plasmid (CMV-LacZ), ALK4 (activin receptor-like
kinase-4, a type I receptor) expression plasmid and various
Figure 4 Delivery of N(− ) or NM to adult mice decreased white adipose tissue mass. (a) Images of abdominal fat (stars) among treatment
groups. (b) Quantification of the abdominal fat. An obvious decrease in WAT mass was found after FST vector delivery (24.3% of the
control). Although not as obvious as FST, the WAT mass of N(− ) (48.8% of the control) and NM were significantly decreased (57.1% of
the control). The WAT mass of the FST-I-I group did not change compared with the control (98% of the control). (c) The H&E staining of
white adipose tissue (20× ), scale bar: 100 μm. N=5, *Po0.05, **Po0.01 and *** Po0.001 compared with the control ICR mice.
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FST-based constructs (see the ‘Materials and Methods’ section
for details). Myostatin was supplied in the culture media 8 h
after transfection as conditioned media. As expected, FST
significantly decreased luciferase expression induced by myos-
tatin (27.9% of the control, Po0.0001, Figure 7a). FST-I-I also
significantly inhibited myostatin, albeit to a lesser degree
(45.6% of the control, Po0.01). N(− ) (51.4% of control,
Po0.05) and NM (56.5% of control, P40.05) demonstrated
the least myostatin inhibition.
For the activin neutralization assay, we utilized 293 cells.
Therefore, the myostatin receptor ALK4 plasmid was not
needed. Three plasmids (3TP-Lux, cmv-LacZ and varied
FST-based constructs) were co-transfected into the 293 cells.
Activin was provided in the culture media 8 h after transfection
as conditioned media (see materials and methods for details).
As expected, FST significantly inhibited the luciferase expres-
sion elicited by activin (27.6% of control, Po0.01), whereas
N(− )(48.8% of control, Po0.05) and NM (39.6% of control,
Po0.05) also substantially blocked the luciferase expression.
The FST-I-I construct containing the complete N terminus
displayed minimal activin neutralization effects (74.4% of
control, P40.05) (Figure 7b). The results of our luciferase
reporter assay fully support our hypothesis that the N terminus
of FST is more important for myostatin binding than activin
bioneutralization.
DISCUSSION
FST is recognized as an important regulator of cell secretion,
development and differentiation in a number of tissues and
organ systems. FST functions through its ability to potently bind
and antagonize TGF-β superfamily ligands. TGF-β superfamily
ligands signal by binding to specific cell receptors (two type II
and two type I), which in turn activate the canonical SMAD-
mediated pathway and non-SMAD pathways.36 In addition, the
diverse functions of TGF-β superfamily ligands arise through its
regulation at multiple levels, beginning at the ligands, the
receptors and at the level of transcription activation complex
formation.56 FST was first identified as a potent inhibitor of
activin but is now known to bind other ligands, including
inhibin; bone morphogenetic proteins (BMPs) 2, 4, 6, 7, 11 and
Figure 5 N terminus-mutated or -deleted FSTs had minimal effect on the differentiation of C2C12 myoblasts. (a) Immunofluorescent
staining of differentiated C2C12 myoblasts against dystrophin. The C2C12 cells were cultured under differentiation media supplemented
with conditioned media containing control (GFP) plasmid, mouse-FST, mouse-NM, mouse-N(− ) and mouse-FST-I-I plasmids as indicated
in the figure. We found that C2C12 cells cultured with all FST vectors were larger in diameter than the control. FST and FST-I-I-
conditioned media showed the greatest increase, whereas NM and N(− ) groups were only slightly larger. Scale bar: 100 μm. (b) The
measurement of diameters of differentiated C2C12 myotubes. Myotubes cultured with mouse-FST-conditioned media were 2.1-fold larger,
whereas FST-I-I was 1.8-fold larger, N(− ) was 1.3-fold larger and NM was 1.5-fold larger than the control. *Po0.05, **Po0.01 and
***Po0.001 compared with control ICR mice.
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15; and myostatin, with lower affinities.57–59 Numerous in vitro
structural and biochemical studies have predicted the function
of different domains of FST.36,37,60 For example, by studying
crystal structure, Cash et al.36 reported that the N-terminal
domain of FST undergoes conformational rearrangements to
bind myostatin and likely acts as a site of specificity for the
antagonist. Utilizing an in vitro bioassay system, Sidis et al.37
demonstrated that the N-terminal domain of FST had an
essential role in activin binding and neutralization. To our
knowledge, this was the first study to provide direct in vivo
evidence reflecting the importance of the N-terminal of FST in
regulating biological effects of myostatin and activin.
The most important finding of our study was that N(− ) or
NM constructs did not increase muscle weight, yet decreased
white fat mass in vivo. It is well known that FST can significantly
increase skeletal muscle weight in vivo partly through blockade of
myostatin.12,61 Our data imply that ND is critical for myostatin
binding, and therefore, the N terminus-deleted or -mutated FST
constructs failed to increase muscle mass. This further validates
the importance of ND in the interaction of FST with myostatin
by blocking type I receptor binding sites as revealed by crystal
structure.36 In contrast, the FST-I-I construct with the complete
N terminus and lacking domain II and domain III increased
skeletal muscle mass while leaving the white fat weight
unchanged. Our data are in agreement with other studies
indicating that transgenic expression of the FST-I-I construct
increases skeletal muscle mass.35 However, the FST-I-I transgenic
mice also displayed decreased fat accumulation, which is different
Figure 6 Minimal involvement of relevant signaling pathways by N terminus-mutated or -deleted FSTs in differentiated C2C12 myoblasts.
(a) Western blot against P-Smad2/3 and total SMADs in differentiated C2C12 myoblasts. (b) Semi-quantification of pSmad expression
shown in the western blot as the ratio of P-Smad2/3 to total Smads. Compared with the control, the ratio of P-Smad2/3 to total Smads
was downregulated by FST to 74.4% and FST-I-I to 84.2%, indicating the Smad pathway inhibition, whereas N(− ) and NM groups did
not change much (the ratio was 94.7% and 97.9%, respectively). (c) Western blot against P-AKT and total AKT in differentiated myoblast.
(d) Semi-quantification of pAKT expression. The ratio of P-AKT to total AKT was greatly activated by FST followed by FST-I-I, N(− ) and
NM. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001 compared with control.
Figure 7 The effect of various FST-based constructs on the Smad luciferase reporter assay. (a) The myostatin blockade reporter assay. The
L17R-1B cells were utilized here, and myostatin was provided as the conditioned media. FST and FST-I-I significantly inhibited the
luciferase expression induced by myostatin to 27.9% and 45.6% of the control, respectively. NM (56.5%) or N(− ) (51.4%) had milder
blockade effects against myostatin. (b) Activin blockade reporter assay. The 293 cells were used here, and the activin was supplied as the
conditioned media. FST significantly decreased luciferase expression induced by activin to 27.6% of the control, followed by N(− )(48.8%
of the control) and NM (39.6% of the control). FST-I-I (74.4% of the control) had no significant activin inhibitory effects. *Po0.05,
**Po0.01, ***Po0.001 and ****Po0.0001 compared with control.
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from our finding that fat weight was unchanged.34 We believe the
discrepancy is due to the degree of myostatin inhibition in fat
tissue. Transgenic technology would result in stronger myostatin
inhibition than gene transfer, which was used in our study.
Further investigation involving higher vector dosage and earlier
intervention (such as neonatal treatment) with the same vector
should resolve the discrepancy. Nevertheless, our data suggest the
essential role that ND had in blockade of myostatin.
There is a debate as to how critical the ND is to the
interaction of FST with activin. In one instance, deletion or
mutation of the N-terminal domain of FST prevented activin
binding and failed to suppress the bioactivity of activin in vitro.37
Other studies indicate that FST domains I and II are the major
contributors to FST-activin interactions.62,63 In the present
study, we performed an in vivo experiment revealing that both
N(− ) and NM could significantly decrease white fat mass. The
mechanism by which FST decreases white fat tissue is compli-
cated given that numerous FST binding ligands are involved in
adipocyte development, adiposity and energy expenditure.64
Considering both N(− ) and NM had limited ability to block
myostatin, we hypothesized that the fat decreasing effect
observed in those two groups were mainly through binding
with activin, which possesses a strong binding affinity to FST.
Our in vitro Smad reporter assay revealed that both constructs
could inhibit luciferase activity induced by activin, indicating
both could bind with activin. Therefore, our study indicates that
the N-terminal domain of FST is not critical for binding activin.
In summary, TGF-β superfamily members and their related
signal transduction pathways have gained great attention in
adipogenesis, mature adipocyte function, pancreatic β-cell
proliferation, as well as muscle pathogenesis in recent years.
Blockade of the TGF-β transduction pathway through FST is
an emerging therapeutic avenue for treating diabetes and
muscular dystrophies. Our results will provide further evidence
for rational designs of FST-based therapies.
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